Cagrilintide

Cagrilintide is a novel, long-acting amylin analogue developed for weight loss and metabolic support. It works by mimicking the hormone amylin, enhancing satiety and reducing caloric intake. Clinical trials have demonstrated robust weight reduction, especially when co-administered with semaglutide. Still investigational, it shows promise in future obesity pharmacotherapy pipelines. It is often combined with GLP-1 agonists in research settings for additive effects on satiety

• Amylin receptor agonist
• Delays gastric emptying and suppresses glucagon
• Enhances satiety via CNS signaling
• Reduces food intake and modulates energy balance

• unit: mg

  low dose: 0.25

  frequency: Weekly

  high dose: 4.5

  standard dose: 1

  administration route: Subcutaneous (SQ)

• Inject once weekly; cycle continuously with physician monitoring. Adjust dose upward gradually based on GI tolerance and weight response. Often paired with GLP-1 analogues like semaglutide for synergy.

common: ["Nausea (47–55%), vomiting (26%), diarrhea, constipation, abdominal pain"]

warnings: ["79.6% GI events with CagriSema combo vs 39.9% placebo"]

sequence: N/A

half life: Estimated 4–7 days supporting weekly dosing

degradation: Metabolized primarily by proteolytic enzymes

molecular weight: 3962.33

molecular formula: C173H271N51O53S1

tissue specificity: Targets hypothalamic satiety centers and gastric pathways

• Once-weekly cagrilintide for weight management: a phase 2 trial.clinicalPMID 34798060 ↗
• Development of Cagrilintide, a Long-Acting Amylin Analogue.mechanismPMID 34288673 ↗
• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.reviewPMID 36883831 ↗